P4855
Poly(ADP-ribose) Polymerase Automodified bovine
solution
Synonym(s):
PARP
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
form
solution
Application
Positive control for immunoblotting techniques. A streak of M.W. > 116 kDa is detected by immunoblotting, representing PARP modified to various extents by poly(ADP-ribose). Recommended use: 5-20 μl per gel lane.
Other Notes
Partially purified bovine PARP, automodified by the addition of NAD and necessary cofactors.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
inhibitor
Product No.
Description
Pricing
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Dermal - Aquatic Chronic 3 - Eye Dam. 1 - Repr. 2 - Skin Sens. 1
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Carla O Contreras-Ochoa et al.
Experimental parasitology, 134(2), 256-265 (2013-03-30)
Toxoplasma gondii invades any nucleated cell, but different replication speed and effects on survival/apoptosis processes have been found depending on cell type. There are scarce and controversial results regarding the effect of this parasite on host cell apoptosis within the
Sabine Mueller et al.
Anticancer research, 33(3), 755-762 (2013-03-14)
To assess poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 together with radiation for the treatment of neuroblastoma. Clonogenic survival assays were used to assess MK-4827, radiation and combination thereof in four neuroblastoma cell lines. In vivo efficacy was tested in a
Andrew Voronkov et al.
Journal of medicinal chemistry, 56(7), 3012-3023 (2013-03-12)
Tankyrases 1 and 2 (TNKS1/2) are promising pharmacological biotargets with possible applications for the development of novel anticancer therapeutics. A focused structure-activity relationship study was conducted based on the tankyrase inhibitor JW74 (1). Chemical analoging of 1 improved the 1,2,4-triazole
Na Ye et al.
Journal of medicinal chemistry, 56(7), 2885-2903 (2013-03-12)
A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors. The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity
Judith Michels et al.
Cancer research, 73(7), 2271-2280 (2013-04-05)
Non-small cell lung carcinoma patients are frequently treated with cisplatin (CDDP), most often yielding temporary clinical responses. Here, we show that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service